These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32884128)

  • 1. Liver biopsy findings in patients on immune checkpoint inhibitors.
    Cohen JV; Dougan M; Zubiri L; Reynolds KL; Sullivan RJ; Misdraji J
    Mod Pathol; 2021 Feb; 34(2):426-437. PubMed ID: 32884128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic immune-mediatedadverseeffects of immune checkpoint inhibitors: analysis of real-life experience.
    da Silva JA; Falcão D; Cardoso C; Pires AL; Araújo A; Castro-Poças F
    Ann Hepatol; 2021 Dec; 26():100561. PubMed ID: 34653687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morphology of immune-mediated hepatitis: A comparison between immune checkpoint inhibitor therapy and combined immune checkpoint inhibitor/anti-angiogenic therapy.
    Zhang Q; Chen L; Guo X; Shen L; Huang Y; Chen Y; Zhang N; Ge N; Gao H; Zhang W; Hou Y; Ji Y
    Ann Diagn Pathol; 2024 Feb; 68():152225. PubMed ID: 38016303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies.
    Mizuno K; Ito T; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Kawashima H; Inukai Y; Toyoda H; Yokota K; Hase T; Maeda O; Kiyoi H; Nagino M; Hibi H; Kodera Y; Fujimoto Y; Sone M; Gotoh M; Ando Y; Akiyama M; Hasegawa Y; Fujishiro M
    J Gastroenterol; 2020 Jun; 55(6):653-661. PubMed ID: 32124082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ipilimumab-associated Hepatitis: Clinicopathologic Characterization in a Series of 11 Cases.
    Johncilla M; Misdraji J; Pratt DS; Agoston AT; Lauwers GY; Srivastava A; Doyle LA
    Am J Surg Pathol; 2015 Aug; 39(8):1075-84. PubMed ID: 26034866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency and pathological characteristics of drug-induced liver injury in a tertiary medical center.
    Ettel M; Gonzalez GA; Gera S; Eze O; Sigal S; Park JS; Xu R
    Hum Pathol; 2017 Oct; 68():92-98. PubMed ID: 28873351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Features of Liver Injury Induced by Immune Checkpoint Inhibitors in Japanese Patients.
    Imoto K; Kohjima M; Hioki T; Kurashige T; Kurokawa M; Tashiro S; Suzuki H; Kuwano A; Tanaka M; Okada S; Kato M; Ogawa Y
    Can J Gastroenterol Hepatol; 2019; 2019():6391712. PubMed ID: 31929981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical features of immune-mediated hepatotoxicity induced by immune checkpoint inhibitors in patients with cancers.
    Yamamoto A; Yano Y; Ueda Y; Yasutomi E; Hatazawa Y; Hayashi H; Yoshida R; Asaji N; Shiomi Y; Tobimatsu K; Sakai A; Kodama Y
    J Cancer Res Clin Oncol; 2021 Jun; 147(6):1747-1756. PubMed ID: 33222015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors - A territory-wide cohort study.
    Chan SL; Yip TC; Wong VW; Tse YK; Yuen BW; Luk HW; Lui RN; Chan HL; Mok TS; Wong GL
    Cancer Med; 2020 Oct; 9(19):7052-7061. PubMed ID: 32780516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Something old, something new: liver injury associated with total parenteral nutrition therapy and immune checkpoint inhibitors.
    Meyerson C; Naini BV
    Hum Pathol; 2020 Feb; 96():39-47. PubMed ID: 31669893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development.
    Regev A; Avigan MI; Kiazand A; Vierling JM; Lewis JH; Omokaro SO; Di Bisceglie AM; Fontana RJ; Bonkovsky HL; Freston JW; Uetrecht JP; Miller ED; Pehlivanov ND; Haque SA; Harrison MJ; Kullak-Ublick GA; Li H; Patel NN; Patwardhan M; Price KD; Watkins PB; Chalasani NP
    J Autoimmun; 2020 Nov; 114():102514. PubMed ID: 32768244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignancies.
    Ito T; Ishigami M; Yamamoto T; Mizuno K; Yamamoto K; Imai N; Ishizu Y; Honda T; Kawashima H; Yasuda S; Toyoda H; Yokota K; Hase T; Nishio N; Maeda O; Kato M; Hashimoto N; Hibi H; Kodera Y; Sone M; Ando Y; Akiyama M; Shimoyama Y; Fujishiro M
    Hepatol Int; 2021 Oct; 15(5):1278-1287. PubMed ID: 34373964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histologic features of allograft livers in patients treated for rejection before biopsy.
    Leonard NB; Hale GL; Boylan KE; Ou Z; Zhang C; Kim R; Chandna S; Dong ZM; Evason KJ
    Hum Pathol; 2023 May; 135():11-21. PubMed ID: 36804507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Follow-up biopsies in gastrointestinal immune checkpoint inhibitor toxicity may show markedly different inflammatory patterns than initial injury.
    Tomm NK; Szczepanski JM; Fang JM; Choi WT; Xue Y; Setia N; Karamchandani DM; Cheng JY; Westerhoff M
    Hum Pathol; 2024 Jun; 148():60-65. PubMed ID: 38734079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort.
    Hountondji L; Ferreira De Matos C; Lebossé F; Quantin X; Lesage C; Palassin P; Rivet V; Faure S; Pageaux GP; Assenat É; Alric L; Zahhaf A; Larrey D; Witkowski Durand Viel P; Riviere B; Janick S; Dalle S; Maria ATJ; Comont T; Meunier L
    JHEP Rep; 2023 Jun; 5(6):100719. PubMed ID: 37138674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deciphering the Dynamic Complexities of the Liver Microenvironment - Toward a Better Understanding of Immune-Mediated liver Injury Caused by Immune Checkpoint Inhibitors (ILICI).
    Wang T; Yeh MM; Avigan MI; Pelosof L; Feldman GM
    AAPS J; 2021 Aug; 23(5):99. PubMed ID: 34401948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycophenolate mofetil for immune checkpoint inhibitor-related hepatotoxicity relapsing during dose reduction of corticosteroid: A report of two cases and literature review.
    Ueno M; Takabatake H; Hata A; Kayahara T; Morimoto Y; Notohara K; Mizuno M
    Cancer Rep (Hoboken); 2022 Sep; 5(9):e1624. PubMed ID: 35575047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury.
    Zen Y; Yeh MM
    Mod Pathol; 2018 Jun; 31(6):965-973. PubMed ID: 29403081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and Pathological Features of Immune Checkpoint Inhibitor-induced Liver Injury in Comparison with Drug-induced Liver Injury and Autoimmune Hepatitis.
    Sunago K; Abe M; Yoshida O; Watanabe T; Nakamura Y; Imai Y; Koizumi Y; Hirooka M; Tokumoto Y; Hiasa Y
    J Gastrointestin Liver Dis; 2023 Dec; 32(4):488-496. PubMed ID: 38147620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis.
    Li M; Sack JS; Rahma OE; Hodi FS; Zucker SD; Grover S
    Cancer; 2020 Dec; 126(23):5088-5097. PubMed ID: 32888341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.